This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): memantine
Description: FP01 is an oral drug product in use for another disease. Given its unique mechanism of action, FP01 as currently used is notable for its lack of side effects and minimal abuse potential, issues that plague medicines currently available for treating cough. The currently marketed form of FP01 has a long lag time to peak effect - limiting its potential utility in acute cough. Cerecor's intellectual property portfolio consists of patent applications which cover cough method-of–use, in addition to synergistic combinations and cough formulations of FP01 which enable its utility in cough.
In preclinical studies, Cerecor has demonstrated that FP01 is an extremely potent antitussive in animals and produces no observable signs of sedation or behavioral changes.
While the company has not released the active compound, it appears to be memantine.
Deal Structure: Fells Labs originally licensed the FP01 intellectual property from the Johns Hopkins University.
In May 2011, Cerecor announced the acquisition of intellectual property assets comprising FP01 from Fells Laboratories. Under the terms of the agreement, after an upfront payment, additional consideration is to be paid to Fells upon milestone achievement.
Partners: Fells Laboratories, LLC
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Pink Sheet FDA Performance Tracker: CBER Approvals
Additional information available to subscribers only: